Amedisys (AMED) Reaffirms FY08 Sales, EPS Guidance
More News related to AMED
- Amedisys to Present at the 27th Annual J.P. Morgan Healthcare Conference
- XplosiveStocks.com: AMED, EQIX, PCLN, RIMM, IDEV, JAVA Hot Stocks on the Move
- Morning Movers 1/06: Indevus Pharmaceuticals (IDEV) Soars On Buyout, Garmin (GRMN) Lower on Downgrade
- BenchmarkJournal.com (Complimentary) Analyst Review for IDEV, AMED, ENDP and CIEN
- Amedisys (AMED) Issues Strong '09 Guidance
More News related to Guidance
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
Amedisys, Inc. (Nasdaq: AMED) reaffirms its previously issued FY08 sales guidance of $1.15-$1.175 billion, versus the consensus of $1.17 billion, and EPS of $3.20-$3.25, versus the Street estimate of $3.24.
Amedisys, Inc. provides home health and hospice services in the United States.
Related Categories
GuidanceStocks Mentioned
+1.93Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
